Seeking Alpha·2025-12-01 13:00Company Overview - Harrow, Inc. (HROW) is an emerging leader in FDA approved branded ophthalmic pharmaceuticals, having transitioned from an ophthalmic compounding pharmacy since its inception in 2015 [1] - The company currently holds approximately 35% market share in its niche, which is significantly larger than its competitors, estimated to be around 10 times their share [1] Investment Philosophy - The investment approach reflects principles similar to those of renowned investors Warren Buffett and Charlie Munger, focusing on a select group of companies with which the analyst has developed a long-standing familiarity [1] - The analyst emphasizes the importance of maintaining composure during market panics, suggesting that current market conditions present a favorable investment opportunity [1]